Document is current
Any future updates will be listed below
-
Authors
Koscova, Zuzana
Li, Qiao
Robichaux, Chad
Junior, Valdery Moura https://orcid.org/0000-0001-5735-9143
Ghanta, Manohar
Gupta, Aditya https://orcid.org/0000-0002-5243-368X
Rosand, Jonathan
Aguirre, Aaron D.
Reinertsen, Erik
Song, Steven
Hong, Shenda
Albert, David E.
Xue, Joel
Parekh, Aarya
Sameni, Reza
Reyna, Matthew A. https://orcid.org/0000-0003-4688-7965
Westover, M. Brandon
Clifford, Gari D.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL161253)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL161253)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB030362)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB030362)
- License Information
-
More Information
Article History
Received: 5 September 2025
Accepted: 6 February 2026
First Online: 25 February 2026
Competing interests
: M.B.W. is a co-founder, scientific advisor, and consultant to Beacon Biosignals and has a personal equity interest in the company. D.E.A. is the founder and Chief Medical Officer of AliveCor Inc. and holds personal equity in the company. J.X. is a research fellow at Alivecor Inc. and also holds personal equity in the company. G.D.C. holds significant stock in AliveCor Inc. The other authors report no competing interests.
